AstraZeneca PLC vs Viking Therapeutics, Inc.: SG&A Expense Trends

SG&A Expense Trends: AstraZeneca vs. Viking Therapeutics

In the ever-evolving pharmaceutical industry, understanding the financial strategies of key players is crucial. Over the past decade, AstraZeneca PLC and Viking Therapeutics, Inc. have showcased contrasting trends in their Selling, General, and Administrative (SG&A) expenses. AstraZeneca, a global leader, has seen its SG&A expenses grow by approximately 35% from 2014 to 2023, peaking in 2022. This reflects its expansive market strategies and robust R&D investments. In contrast, Viking Therapeutics, a smaller biotech firm, has experienced a staggering 2,870% increase in SG&A expenses over the same period, indicating aggressive growth and scaling efforts. While AstraZeneca's expenses are significantly higher, Viking's rapid percentage increase highlights its dynamic approach in a competitive market. These trends offer a glimpse into the strategic priorities of these companies, with AstraZeneca focusing on consolidation and Viking on expansion.